Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, Health Canada and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 According to a ... for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, ... TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global ... - 2019," the global electrodes market for medical devices ... is estimated to reach a market worth USD 1,451.2 ...
(Date:7/31/2014)... Senomyx , Inc. (NASDAQ: ... taste science technologies to discover, develop, and commercialize ... ingredient supply industries, today reported financial results for ... second quarter with $33.6 million in cash and ... past quarter Senomyx achieved another important milestone with ...
(Date:7/31/2014)... Francisco, Calif. (PRWEB) July 31, 2014 ... newly diagnosed patients with an overview of the disease ... management of drug side effects, as well as updates ... “We’re grateful to Dr. Sandy Srinivas for organizing this ... survivor of kidney cancer. “Sandy and her colleagues have ...
(Date:7/31/2014)... July 31, 2014 Although RNA-Sequencing ... the first transcriptome-wide analyses appearing around 2008, RNA-Sequencing ... for RNA measurement. In the last several years, ... specific, work with smaller input amounts, process degraded ... blood samples). On the bioinformatics side, there have ...
Breaking Biology Technology:Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
... BioFuel Energy Corp. (Nasdaq:,BIOF) announced today that ... Wednesday, November 7, 2007, after the market closes. ... plans to host a conference call on Thursday, ... discuss the third quarter results. To,participate, please dial ...
... SAN DIEGO, Nov. 1 Anadys Pharmaceuticals,Inc. (Nasdaq: ... improving,patient care by developing novel medicines in the ... financial results for the third quarter ended,September 30, ... of 2007 marked an important transition for Anadys,",said ...
... SOUTH SAN FRANCISCO, Calif., Nov. 1 Renovis,Inc. (Nasdaq: ... will,present an overview of the company at the CIBC ... Wednesday, November 7, 2007 at 11:30,a.m. Eastern Standard Time ... access the live audio broadcast and the subsequent archived ...
Cached Biology Technology:Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 8Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 9
(Date:7/30/2014)... (SALSI), a joint venture between The University of Texas ... Health Science Center at San Antonio, has selected the ... Emily Boice from UTSA and Lei Huang from the ... titled, "Novel engineered ferritins for tracking and protecting neural ... research is focused on finding a treatment for stroke ...
(Date:7/30/2014)... female baboons suggests that the route to a higher rank ... lots of supportive sisters. , A female baboon,s social status ... rank of her mother - the higher the mother is ... dominance rank in female baboons is thought to be determined ... good spot in the pecking order, whereas females born to ...
(Date:7/30/2014)... of biologists, led by Clemson University associate professor Andrew ... that will pave the way for novel anti-fouling paint ... medical and industrial applications. , The team,s findings, published ... last larval stage of barnacles that attaches to a ... polymeric material that acts as an underwater heavy-duty adhesive. ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... (Jan. 18, 2012) The National Eye Institute has ... subsidiary of Mass. Eye and Ear, a five year-grant ... of eye allergies (NEI Grant Number 1R01EY021798-01A1). Daniel ... the project formally entitled "Cellular and Molecular Mechanisms that ...
... Visualize this ASU classroom: a dark green Panamanian tropical ... sloth moves overhead so slowly that a leaf nearby spins ... Monkey poop, parrot feathers and leaf matter rain down, startling ... forest floor alongside six teams of students from ASU,s ...
... such as switchgrass and Miscanthus has focused mainly ... fuels. But many steps lead from the farm to the ... this new industry. A new computer model developed at the ... model can run millions of simulations, optimizing operations to bring ...
Cached Biology News:Tropical classroom inspires exhibit, Smithsonian field station design 2Tropical classroom inspires exhibit, Smithsonian field station design 3From field to biorefinery: Computer model optimizes biofuel operations 2From field to biorefinery: Computer model optimizes biofuel operations 3